Oncology Business Management | Specialty

The OncLive Oncology Business Management condition center page is a comprehensive resource for news and expert insights on business-focused updates and topics in oncology practices, including diversity efforts, telehealth, gaps in care, payment models, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates and best practices with oncology business management.

Durvalumab Granted Breakthrough Status for Bladder Cancer

February 17th 2016

The FDA has granted a breakthrough therapy designation to durvalumab as a treatment for patients with PD-L1â€“positive inoperable or metastatic urothelial bladder cancer following progression on prior treatment with a platinum-based regimen.

Second Partnership Was the Charm for Seattle Oncology Practice

February 14th 2016

For one group of physicians in Seattle, hooking up with US Oncology seemed like a good idea at first, until circumstances changed and the deal no longer was a benefit for any of the partners.

FDA Places Pacritinib on Full Clinical Hold

February 13th 2016

The FDA has placed a full clinical hold on trials exploring pacritinib, following reports of patient deaths related to intracranial hemorrhage, cardiac failure, and cardiac arrest in the phase III PERSIST-2 trial.

Bankruptcy in Cancer Survivors

February 13th 2016

Matthew Banegas, PhD, MPH, discusses a recent study that found that a considerable number of working-age adults who survive cancer and its toxic treatments, end up with substantial medical debts or declare bankruptcy.

FDA Schedules ODAC Meeting for Rociletinib in NSCLC

February 12th 2016

The FDA has scheduled an ODAC advisory hearing for April 12, 2016, to discuss the new drug application for rociletinib as a treatment for patients with metastatic EGFR T790M-mutated nonâ€“small cell lung cancer.

Cautious Evolution Underway in DTC Genetic Testing

February 12th 2016

Changes are brewing again in the direct-to-consumer genetic testing industry including developments with the potential to affect the public in the oncology field.

FDA Grants T-Cell Therapy Breakthrough Designation in Sarcoma

February 9th 2016

An affinity enhanced T-cell therapy has received an FDA breakthrough therapy designation for the treatment of patients with inoperable or metastatic pretreated synovial sarcoma who harbor HLA-A*201, HLA-A*205, or HLA-A*206 alleles and whose tumors express the NY-ESO-1 tumor antigen.

FDA Approves Single-Dose Fosaprepitant for CINV

February 4th 2016

The FDA approved single-dose fosaprepitant dimeglumine (Emend for injection) in combination with other antiemetic agents for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC), according to Merck, the developer of the drug.

FDA Issues Complete Response Letter for Immunotherapy MCNA in Bladder Cancer

February 3rd 2016

The FDA issued a complete response letter to Telesta Therapeutics informing the company that its biologics license application for MCNA in bladder cancer would not be approved and that an additional phase III clinical trial was needed to adequately evaluate the immunotherapy.

FDA Grants Venetoclax Breakthrough Designation in AML

January 28th 2016

Venetoclax has received an FDA breakthrough therapy designation for use in combination with hypomethylating agents in treatment-naÃ¯ve patients with acute myeloid leukemia who are not eligible for standard high-dose induction treatment.

FDA Grants Cabozantinib Priority Review for RCC

January 28th 2016

The FDA has granted a priority review designation to cabozantinib as a treatment for patients with advanced renal cell carcinoma following progression on one prior therapy.

FDA Approves Eribulin for Advanced Liposarcoma

January 28th 2016

The FDA has approved eribulin mesylate as a treatment for patients with advanced or unresectable liposarcoma following prior treatment with an anthracycline-based chemotherapy.

FDA Grants Olaparib Breakthrough Designation in mCRPC

January 28th 2016

Olaparib (Lynparza) has received an FDA breakthrough therapy designation as a treatment for patients with BRCA1/2 or ATM-mutated metastatic castration-resistant prostate cancer in those who have received a prior taxane-based chemotherapy and at least either hormonal agent enzalutamide (Xtandi) or abiraterone acetate (Zytiga).

Michael J. Hennessy Associates Launches The Institute for Value-Based Medicine to Translate Evidence-Based Research into Value-Based Decisions

January 27th 2016

Michael J. Hennessy Associates, Inc., a full-service health care communications company offering education, research and medical media, introduces The Institute for Value-Based Medicine, a comprehensive online source of timely data, information and perspectives related to value-based medicine.

FDA Expands Nivolumab's Frontline Melanoma Approval to Include BRAF-Mutant Patients

January 23rd 2016

The FDA has expanded the frontline melanoma indications for nivolumab as a single agent and in combination with ipilimumab to include patients with BRAF mutations.

FDA Grants Priority Review to Lenvatinib/Everolimus Combo for RCC

January 18th 2016

The FDA has granted a priority review designation to the combination of lenvatinib and everolimus as a treatment for patients with metastatic renal cell carcinoma following one prior VEGF-targeted therapy.

Lenvatinib/Everolimus Combo Submitted for Approval in Advanced RCC

January 15th 2016

Regulatory filings have been submitted in the United States and Europe for the combination of lenvatinib and everolimus as a treatment for patients with metastatic renal cell carcinoma following a VEGF-targeted therapy.

Clinical Decision Support Tools Deliver Benefits Beyond Improved Patient Care

January 14th 2016

One best practice identified for transforming quality, safety and efficiency in healthcare is the use of clinical decision support tools.

FDA Grants Venetoclax Priority Review in Second-Line CLL

January 12th 2016

The FDA has assigned a priority review to venetoclax for use in adults with chronic lymphocytic leukemia, including patients with a 17p deletion, following at least 1 prior therapy.

FDA Approves Alcohol-Free Docetaxel Formulation

December 28th 2015

The FDA has approved a non-alcohol formulation of docetaxel as a treatment for patients with breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.